Sign In
Buy ARDX
$6.18
-0.190 (-2.98%)
At Close: Jun 23, 2026
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach
08:07am, Thursday, 04'th Jun 2026
Ardelyx NASDAQ: ARDX executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
08:01am, Tuesday, 19'th May 2026
WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercia
Ardelyx: Low Price, But High Implied Valuation
10:55am, Friday, 08'th May 2026
Ardelyx (ARDX) is rated Buy, driven by robust commercial execution of IBSRELA and XPHOZAH, and management's $1B revenue target by FY2029. ARDX's ACCEL Phase III trial offers significant upside optiona
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings
08:01am, Thursday, 07'th May 2026
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines tha
Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
10:01pm, Thursday, 30'th Apr 2026
Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue Estimates
07:26pm, Thursday, 30'th Apr 2026
Ardelyx (ARDX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.17 per share a year ago.
Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics
07:01pm, Thursday, 30'th Apr 2026
While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare t
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
04:01pm, Thursday, 30'th Apr 2026
Q1 2026 total product revenue of $93.4 million, reflecting 38% growth year-over-year IBSRELA Q1 2026 revenue growth of 58% year-over-year to $70.1 million; Reiterating guidance of $410-$430 million
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Tuesday, 28'th Apr 2026
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings
08:01am, Monday, 27'th Apr 2026
Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select
Will Ardelyx (ARDX) Report Negative Earnings Next Week? What You Should Know
11:03am, Thursday, 23'rd Apr 2026
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
08:01am, Thursday, 23'rd Apr 2026
WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines t
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
08:00am, Monday, 20'th Apr 2026
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet signific
Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
08:01am, Thursday, 16'th Apr 2026
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commer
Ardelyx President and CEO Sells 41,000 Shares for $243,000
11:11am, Friday, 03'rd Apr 2026
Michael Raab sold 41,666 shares of common stock for a total of approximately $243,000, with the transaction executed at around $5.84 per share on March 16, 2026. The transaction represented 2.21% of M
